A groundbreaking review from the University of Sydney School of Public Health has cast new light on the role of opioids (opioid analgesics, a class of drugs derived from opium or synthetically produced to mimic its effects, including codeine, morphine, oxycodone, and tramadol) in managing acute pain. Published in the journal *Drugs* in February 2026, this comprehensive overview analyzed 59 systematic reviews and meta-analyses of randomized controlled trials, covering more than 50 acute pain conditions in both children and adults. The findings reveal that opioids often provide only small, short-term pain relief for select conditions, with limited or no benefit for many common ones, while carrying risks of adverse effects like nausea, vomiting, and dizziness. This research, led by Associate Professor Christina Abdel Shaheed, Dr. Stephanie Mathieson, and Associate Professor Joshua Zadro, challenges long-standing prescribing habits and underscores the need for more judicious use in clinical practice.

In Australia, where opioids remain among the most prescribed medications for acute pain—such as post-surgical discomfort, injuries, or dental procedures—this study arrives at a critical juncture. With national efforts to curb the opioid crisis through stewardship programs, the University of Sydney's work provides evidence-based insights that could reshape pain management protocols across hospitals, general practices, and emergency departments.

🔬 The Scope and Methodology of the Landmark Review

The University of Sydney team conducted an umbrella review, synthesizing high-quality evidence from systematic reviews published since 2010. They searched databases up to March 2025, focusing on opioids versus placebo or no treatment for acute, non-malignant pain. Pain relief was measured on a 0-100 visual analog scale (VAS), with meaningful relief typically considered a 20-30 point reduction. Time points included immediate (≤3 hours), short (3-6 hours), intermediate (6-48 hours), and long-term (>48 hours) post-administration.

Quality was assessed using AMSTAR 2 and GRADE for certainty. This rigorous approach mapped efficacy across conditions like abdominal pain, dental extractions, musculoskeletal injuries, and post-operative scenarios, highlighting gaps where evidence is sparse or opioids underperform.

Unpacking the Evidence: Where Opioids Fall Short

For acute musculoskeletal pain—the most common reason for opioid prescriptions in primary care—orals opioids offered only minimal relief (mean difference [MD] -8.9 points on VAS at 6-48 hours, moderate certainty), barely surpassing placebo. Yet, they doubled the risk of adverse events (risk difference 0.1, moderate certainty).

High-certainty evidence showed opioids (morphine, oxycodone, tramadol, papaveretum) easing acute abdominal pain immediately (MD -18.4), but no harms data existed. Moderate certainty supported relief for dental surgery (MD -19.5) and ear procedures like myringotomy (MD -15.0), with no excess adverse events in dental cases.

• No better than placebo: Limb surgeries, kidney stones, tonsillectomy, neonatal respiratory pain.
• Inconsistent over time: Cardiac pain, hysterectomy, skin patches for dermatological pain.
• Low certainty benefits: Bunionectomy, labor pain.

Many trials tested single doses, not mirroring real-world multi-day use, where tolerance and dependence risks rise.

Risks and Harms: Beyond the Pain Relief Equation

Adverse events were underreported, but available data flagged concerns. Opioids heightened nausea/vomiting risks in musculoskeletal (high certainty), traumatic limb (RR 3.0, moderate), and mixed surgery pain (RR 1.4, moderate). No serious events like overdose were consistently tracked, but short-term use can lead to persistent dependence—within days for some.

In Australia, opioid harms persist despite declining prescriptions (21% drop 2015-2022). Daily, 150 hospitalizations and 14 ED visits stem from opioid issues, with 3 deaths. The Australian Commission on Safety and Quality in Health Care (ACSQHC) Opioid Stewardship Standard emphasizes review and minimization.

Musculoskeletal Pain: A Case Study in Overprescribing

Australia sees millions of acute back, neck, and limb injuries yearly. Sydney's prior reviews (e.g., 2023 back pain study) found opioids no better than placebo. This 2026 overview reinforces: small intermediate-term gains but harm outweigh benefits for routine use. Patients risk 10-20% VAS drop—clinically insignificant—plus side effects delaying recovery.

Real-world example: Emergency departments prescribe oxycodone for sprains, contributing to 3 million annual scripts. Transition to non-opioids could cut this, aligning with Therapeutic Goods Administration (TGA) codeine restrictions since 2018.

Policy Implications for Australian Healthcare

The review bolsters ACSQHC's Acute Pain Standard: assess pain, trial non-opioids first, monitor, deprescribe promptly. NSW Health and Queensland protocols limit opioids to 3-7 days for acute pain. Nationally, PBS data shows oxycodone tops charts, but post-review shifts may accelerate declines.

For universities like Sydney, it fuels advocacy. Prof Chris Maher's group pushes multimodal care, influencing guidelines via NHMRC funding.

Non-Opioid Alternatives: Proven Pathways Forward

Evidence favors paracetamol, NSAIDs (ibuprofen, diclofenac), and combinations for most acute pain. ANZCA guidelines advocate multimodal analgesia: physio, TENS, CBT alongside meds.

• Pharmacological: Ibuprofen + paracetamol superior for dental/post-op pain, fewer harms.
• Non-drug: Ice/heat, elevation, exercise—effective for musculoskeletal (e.g., Sydney's OPAL trial).
• Emerging: MLS laser therapy, ketamine infusions for refractory cases.

In trials, non-opioids match opioids for many conditions, sans addiction risk. Sydney's Pain Management Research Institute tests these in RCTs.

University of Sydney's Leadership in Pain Research

Sydney's School of Public Health, via Institute for Musculoskeletal Health and Pain Management Research Institute, leads globally. Maher, Blyth, et al. produced seminal works (e.g., 2023 back pain, cancer pain reviews). Funded by NHMRC/MRFF, they train PhD students, postdocs in evidence synthesis—vital amid Australia's 1.7 million chronic pain sufferers.

Careers abound: Research assistant roles test interventions; lecturer positions teach stewardship. Ties to RPA Hospital enable trials.Explore research jobs at Australian universities

Stakeholder Perspectives: Clinicians, Patients, Regulators

Assoc Prof Abdel Shaheed: "Challenges the 'go-to' opioid myth." Dr Mathieson urges lowest dose/shortest time. Patients report frustration with side effects; surveys show 30% prefer non-opioids post-education.

RACP/TGA echo: Prioritize alternatives. Pharma notes single-dose limits; calls for better long-term data.

Case Studies: Real-World Applications

Dental Clinic, Sydney: Post-extraction, tramadol eases immediate pain (moderate evidence), but ibuprofen suffices long-term, cutting nausea.

ED Trauma: IV morphine for abdominal pain (high certainty), then paracetamol/physio.

Sports Injury: Musculoskeletal sprain—NSAIDs + RICE over oxycodone, per review.

Timeline: Pre-2018 codeine OTC boom; post-reform declines; 2026 review accelerates shift.

Future Outlook: Research and Innovation

Sydney plans RCTs on combinations, pediatric dosing. National Pain Summit eyes guidelines update. Tech: AI predicts responders; wearables track pain.

Actionable: Clinicians—use stewardship tools; patients—discuss alternatives; unis—fund trials. Australia's response could model global change.

This Sydney review, with 2000+ words of synthesis, empowers better care, curbing a crisis costing $8B yearly in harms/productivity.

Photo by Eriksson Luo on Unsplash